In this study, we developed and validated a narrow Next Generation Sequencing gene panel able to cover ALK, ROS1, RET and NTRK gene fusions and MET splicing events in advanced-stage NSCLC patients. Here, ROS1 is linked to non-small cell lung carcinoma.